Revolution Medicines, Inc.

NASDAQ:RVMD

59.1 (USD) • At close November 7, 2024
Bedrijfsnaam Revolution Medicines, Inc.
Symbool RVMD
Munteenheid USD
Prijs 59.1
Beurswaarde 9,872,004,900
Dividendpercentage 0%
52-weken bereik 18.79 - 60.53
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mark A. Goldsmith Ph.D.
Website https://www.revmed.com

An error occurred while fetching data.

Over Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also

Vergelijkbare Aandelen

Zentalis Pharmaceuticals, Inc. logo

Zentalis Pharmaceuticals, Inc.

ZNTL

3.81 USD

Cronos Group Inc. logo

Cronos Group Inc.

CRON

2.06 USD

Atrion Corporation logo

Atrion Corporation

ATRI

459.92 USD

Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc.

MDGL

354.85 USD

Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc.

CLDX

26.47 USD

Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc.

PACB

2.45 USD

Clover Health Investments, Corp. logo

Clover Health Investments, Corp.

CLOV

3.67 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)